Fenwick Represents Juvena Therapeutics in $33.5M Series B Funding

Fenwick represented Juvena Therapeutics, a clinical-stage biotechnology company whose AI-enabled regenerative biologics are designed to restore tissue function, in its $33.5 million Series B financing. The round was led by Bison Ventures with participation from Eli Lilly and Company, Jefferson Life Sciences, Mubadala Capital, and Manta Ray.

Juvena Therapeutics will use the funds to advance its lead clinical programs, expand its pipeline of tissue-restorative biologics, and support continued development of its AI-enabled discovery capabilities. More information can be obtained here.

The Fenwick transaction team was led by corporate partner Matt Rossiter and included associates Kristen Nicol, Adam Conway, Bradley Shepard, and Kosha Patel.